2843 - 1347

The Medicinal Uses of Cannabis and Cannabinoids

Edited by

Geoffrey W Guy

BSc, MB BS, DipPharmMed, MRCS Eng, LRCP, LMSSA

Executive Chairman, GW Pharmaceuticals, Salisbury, Wiltshire, UK

Brian A Whittle

BPharm, MSc, PhD, FRPhS

Scientific Director, GW Pharmaceuticals, Salisbury, Wiltshire, UK

Philip J Robson

MB, MRCP, FRCPsych

Senior Research Fellow, Department of Psychiatry, Oxford University and Medical Director, GW Pharmaceuticals, Salisbury, Wiltshire, UK

London • Chicago Pharmaceutical Press

Contents

Foreword *xi*
Preface *xiii*
Acknowledgements *xvi*
About the editors *xvii*
Contributors *xix*
Introduction *xxi*

1 **History of cannabis as a medicine** 1
Cannabis, the plant 9
Effects of legislation on research 11
References 13

2 **Growth and morphology of medicinal cannabis** 17
Cannabinoids and cannabis anatomy 20
Cannabis life cycle 22
Optimisation of cannabinoid production 23
Why does the plant produce cannabinoids and terpenes? 27
The value of sinsemilla 28
Propagating medicinal cannabis 29
The growing environment 42
Phototropy and photonasty 45
Quality, safety and efficacy: meeting EU Good Agricultural Practice guidelines 48
The way forward – the great outdoors? 50
References 54

3 **The breeding of *Cannabis* cultivars for pharmaceutical end uses** 55
The position of medicinal *Cannabis* breeding 55
Goals and strategies of the pharmaceutical breeding programme 56
Germ plasm resources 60

Current breeding achievements 63
Future developments 67
References 68

4 **The evolution of *Cannabis* and coevolution with the cannabinoid receptor – a hypothesis** 71
Origin of the association 72
Cannabis taxonomy and evolution 73
The species debate 74
Biotypes and cannabinoid profiles 78
Cannabis and cannabinoid receptors 80
The evolutionary arabesque 82
The enigma of animal receptors and plant ligands 84
Deconstructing 'exogenous ligands' 86
Plant ligands and 'the great leap forward' 87
Evidence for coevolutionary adaptations in CB receptors 88
Evidence for coevolutionary adaptations in plant ligands 89
Coevolution makes good medicine 91
Conclusions and future directions 93
References 94

5 **Receptors and pharmacodynamics: natural and synthetic cannabinoids and endocannabinoids** 103
Cannabinoid CB_1 and CB_2 receptors 104
Endogenous ligands for CB_1 and CB_2 receptors 107
Other agonists for CB_1 and CB_2 receptors 114
Chirality of cannabinoids 117
CB_1 and CB_2 receptors antagonists 120
Other cannabinoid receptor ligands 124
Other cannabinoid receptors? 125
Conclusions 128
References 129

6 **Therapeutic potential of cannabis and cannabinoids in experimental models of multiple sclerosis** 141
Cannabis as a therapeutic in MS 142
Symptom control 143
Immunomodulation 150
Neuroprotection 152
References 155

7 **Natural cannabinoids: interactions and effects** 165
Background references 167
Pain 169
Anxiety 172
Depression 177
Alcohol dependence 178
Spasticity 179
Schizophrenia 182
Epilepsy 185
Antioxidant effects 187
Anti-inflammatory effects 191
Conclusions 195
References 197

8 **Metabolism and pharmacokinetics of cannabinoids** 205
Metabolism of Δ^9-THC, cannabidiol, cannabinol and Δ^9-tetrahydrocannabivarin in humans 208
Metabolism *in vitro* in humans 209
Hepatic cytochrome P450s (CYPs) responsible for phase 1 metabolism of cannabinoids 211
Inhibition and induction of oxidative metabolism in the liver by cannabinoids 212
Pharmacokinetics by different routes of administration 216
Routes of administration for CBD and CBN 220
Conclusion 220
References 221

9 **Clinical studies of cannabis-based medicines** 229
Review of existing clinical evidence for therapeutic potential 230
GW Pharmaceuticals patient database 241
Delivery systems for cannabis medicinal extracts 242
Practical issues in initiating a clinical research programme 245
Recently completed human research 254
Future directions for clinical research 260
References 262

10 **Cannabis in the treatment of chronic pain** 271
History 272
Understanding pain 274
Pain assessment and management 280
Starting to study cannabis medicines for pain 282
Influence of cannabis on driving 296
Final comments 296
References 297

11 **The forensic control of cannabis** 301
Analytical aspects of cannabis control 303
Trends in potency of cannabis 304
Analytical techniques 306
Determination of cannabinoids in body fluids for forensic purposes 312
Interpretation of cannabis use in a forensic context 316
Cannabis and driving 324
Quality control of analytical procedures 324
Conclusions 325
References 325

12 **A review of cannabis and driving skills** 329
Forensic control of cannabis and driving 329
Laboratory studies of cognition and motor performance 330
Retrospective analyses of traffic collisions 336
Prospective driving studies 344
Medicinal cannabis and driving 363
References 366

13 **International control of cannabis: changing attitudes** 369
A case study: the United States 370
Social turmoil of the 1960s and a new symbolism 378
International legislation 385
The Conventions and cannabis use 393
What types of cannabis reform are possible? 395
Do international treaties allow cannabis-based medicines to be legally available? 398

What evidence must a country have to make cannabis available as a medicine? 398
What legal changes are necessary to permit the use of medicinal cannabis? 400
Separating the issues of cannabis use 403
Separating medicinal and recreational cannabis use 405
What may drive a change in a nation's attitudes towards cannabis? 406
Relative influence of factors 416
Where are we now? 417
Ending thoughts 424
References 424

14 **Development of cannabis-based medicines: risk, benefit and serendipity** 427
Cannabis as a medicine 428
The historical legacy 431
Regulatory route 438
Quality 442
The dosage form 446
Safety 450
Efficacy 453
Risks, benefits and serendipity 460
References 463

Glossary 467

Index 473

The colour plate section is between pages 232 and 233.